TargetBeta
CDK8
cyclin dependent kinase 8 · also K35 · Cyclin dependent kinases
2 programs in company-led studies act on CDK8, from 1 company: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| SEL-120rule | Ryvu Therapeutics | phase 2 | 73 running | – | NCIt |
| romaciclibrule | Ryvu Therapeutics | phase 2 | 52 running | – | NCIt |
Conditions their studies are in
- Leukemia, Myeloid, Acute, 2 programs
- Primary Myelofibrosis, 2 programs
- Myelodysplastic Syndromes, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026SEL-120 · Ryvu Therapeutics · phase 2 · NCT06987058
- Dec 2026romaciclib · Ryvu Therapeutics · phase 2 · NCT06987058
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.